Recently, the China Pharmaceutical Commercial Association organized the collection of "2024 National Pharmaceutical Industry Digital Transformation Innovation Cases". After enterprise application, preliminary review by the association, expert evaluation, online voting and other processes, Shanghai Hippocrates Health Technology Co., Ltd. successfully had 5 digital transformation cases selected. The specific cases are as follows:

• The Pharmacovigilance Management System (PVS) Project of Beijing Xinlida Pharmaceutical Technology Co., Ltd. was selected as an Excellent Case of Digital Transformation;
• The Cell Therapy Production and Traceability Project (CGT) of Shanghai Kajji Pharmaceutical Co., Ltd., The GMP Training Management (TMS) Project of Suzhou Fushilai Pharmaceutical Co., Ltd., The Contract Manufacturing Quality Management Collaboration (OWL MAH) Project of Kobayashi Pharmaceutical Co., Ltd., and The GMP Quality Compliance Digitalization (QCMS) Project of Zhejiang Zhenyuan Pharmaceutical Co., Ltd. were selected as Outstanding Cases of Digital Transformation.
• Taking this selection as a new starting point, Singdi will deepen its digital transformation, focus on business pain points and integrated management needs, and explore more innovative models. In the future, it will continue to uphold its original aspiration of "utilizing technology to create social health value", take customers as the center, and base itself in the life and health industry (including pharmaceuticals, medical devices, cosmetics, etc.). With unmet market demands as the starting point, Singdi will provide customers with cutting-edge technology-based digital solutions; improve enterprises' quality and compliance levels, reduce costs and operational risks, and promote management intelligence; at the same time, it will assist in the digital transformation of the industry and empower the value chain.